FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361946632> ?p ?o ?g. }

• W4361946632 abstract "<div>Abstract<p><b>Purpose:</b> Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma and includes a <i>PAX3–</i> or <i>PAX7–FOXO1</i> fusion-positive subtype. Amplification of chromosomal region 12q13–q14, which contains the <i>CDK4</i> proto-oncogene, was identified in an aggressive subset of fusion-positive RMS. CDK4/6 inhibitors have antiproliferative activity in <i>CDK4</i>-amplified liposarcoma and neuroblastoma, suggesting CDK4/6 inhibition as a potential therapeutic strategy in fusion-positive RMS.</p><p><b>Experimental Design:</b> We examined the biologic consequences of CDK4 knockdown, CDK4 overexpression, and pharmacologic CDK4/6 inhibition by LEE011 in fusion-positive RMS cell lines and xenografts.</p><p><b>Results:</b> Knockdown of CDK4 abrogated proliferation and transformation of 12q13–14-amplified and nonamplified fusion-positive RMS cells via G₁-phase cell-cycle arrest. This arrest was mediated by reduced RB phosphorylation and E2F-responsive gene expression. Significant differences in E2F target expression, cell-cycle distribution, proliferation, or transformation were not observed in RMS cells overexpressing CDK4. Treatment with LEE011 phenocopied CDK4 knockdown, decreasing viability, RB phosphorylation, and E2F-responsive gene expression and inducing G₁-phase cell-cycle arrest. Although all fusion-positive cell lines showed sensitivity to CDK4/6 inhibition, there was diminished sensitivity associated with CDK4 amplification and overexpression. This variable responsiveness to LEE011 was recapitulated in xenograft models of <i>CDK4</i>-amplified and nonamplified fusion-positive RMS.</p><p><b>Conclusions:</b> Our data demonstrate that CDK4 is necessary but overexpression is not sufficient for RB–E2F–mediated G₁-phase cell-cycle progression, proliferation, and transformation in fusion-positive RMS. Our studies indicate that LEE011 is active in the setting of fusion-positive RMS and suggest that low CDK4-expressing fusion-positive tumors may be particularly susceptible to CDK4/6 inhibition. <i>Clin Cancer Res; 21(21); 4947–59. ©2015 AACR</i>.</p><p><i>See related commentary by Gatz and Shipley, p. 4750</i></p></div>" @default.
• W4361946632 created "2023-04-05" @default.
• W4361946632 creator A5011055578 @default.
• W4361946632 creator A5018687194 @default.
• W4361946632 creator A5025441472 @default.
• W4361946632 creator A5043895259 @default.
• W4361946632 creator A5063835774 @default.
• W4361946632 creator A5074821477 @default.
• W4361946632 date "2023-03-31" @default.
• W4361946632 modified "2023-10-14" @default.
• W4361946632 title "Data from <i>CDK4</i> Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma" @default.
• W4361946632 doi "https://doi.org/10.1158/1078-0432.c.6524078" @default.
• W4361946632 hasPublicationYear "2023" @default.
• W4361946632 type Work @default.
• W4361946632 citedByCount "0" @default.
• W4361946632 crossrefType "posted-content" @default.
• W4361946632 hasAuthorship W4361946632A5011055578 @default.
• W4361946632 hasAuthorship W4361946632A5018687194 @default.
• W4361946632 hasAuthorship W4361946632A5025441472 @default.
• W4361946632 hasAuthorship W4361946632A5043895259 @default.
• W4361946632 hasAuthorship W4361946632A5063835774 @default.
• W4361946632 hasAuthorship W4361946632A5074821477 @default.
• W4361946632 hasConcept C104317684 @default.
• W4361946632 hasConcept C111829193 @default.
• W4361946632 hasConcept C1491633281 @default.
• W4361946632 hasConcept C153911025 @default.
• W4361946632 hasConcept C173396325 @default.
• W4361946632 hasConcept C185592680 @default.
• W4361946632 hasConcept C29537977 @default.
• W4361946632 hasConcept C502942594 @default.
• W4361946632 hasConcept C54355233 @default.
• W4361946632 hasConcept C62112901 @default.
• W4361946632 hasConcept C81885089 @default.
• W4361946632 hasConcept C83258922 @default.
• W4361946632 hasConcept C86803240 @default.
• W4361946632 hasConceptScore W4361946632C104317684 @default.
• W4361946632 hasConceptScore W4361946632C111829193 @default.
• W4361946632 hasConceptScore W4361946632C1491633281 @default.
• W4361946632 hasConceptScore W4361946632C153911025 @default.
• W4361946632 hasConceptScore W4361946632C173396325 @default.
• W4361946632 hasConceptScore W4361946632C185592680 @default.
• W4361946632 hasConceptScore W4361946632C29537977 @default.
• W4361946632 hasConceptScore W4361946632C502942594 @default.
• W4361946632 hasConceptScore W4361946632C54355233 @default.
• W4361946632 hasConceptScore W4361946632C62112901 @default.
• W4361946632 hasConceptScore W4361946632C81885089 @default.
• W4361946632 hasConceptScore W4361946632C83258922 @default.
• W4361946632 hasConceptScore W4361946632C86803240 @default.
• W4361946632 hasLocation W43619466321 @default.
• W4361946632 hasOpenAccess W4361946632 @default.
• W4361946632 hasPrimaryLocation W43619466321 @default.
• W4361946632 hasRelatedWork W1982414245 @default.
• W4361946632 hasRelatedWork W2117441185 @default.
• W4361946632 hasRelatedWork W2291638877 @default.
• W4361946632 hasRelatedWork W2510265744 @default.
• W4361946632 hasRelatedWork W2586385055 @default.
• W4361946632 hasRelatedWork W2783802064 @default.
• W4361946632 hasRelatedWork W3043437927 @default.
• W4361946632 hasRelatedWork W3094951633 @default.
• W4361946632 hasRelatedWork W3130220624 @default.
• W4361946632 hasRelatedWork W4294295793 @default.
• W4361946632 isParatext "false" @default.
• W4361946632 isRetracted "false" @default.
• W4361946632 workType "article" @default.